Sarah Smith

Sarah Smith

Expertise: ESG Investing, Electric Vehicle Stocks, Short Squeeze Stocks

Education: BA, Government and Gender, Sexuality and Women’s Studies, The College of William & Mary

Awards & Accomplishments: Top 5% of stock pickers on TipRanks

About Sarah:
Sarah Smith is an experienced editor and writer who works to help retail investors make sense of what’s happening every day on Wall Street, and she’s particularly interested in ESG investing, EV stocks, and the rise of speculative trading activity like short squeezes. She has also written for Kiplinger.com, Smithsonian, and Washington City Paper. Sarah is currently working to become a Chartered Financial Analyst (CFA) and has already earned bachelor’s degrees in Government and Gender, Sexuality and Women’s Studies from the College of William and Mary. Her work for InvestorPlace.com focuses on helping investors understand the causes and impacts of daily stock and crypto market movements, and how a disruption in who invests – and how they invest – transforms the market. Sarah is recognized among the top 5% of stock pickers on TipRanks and has an average return of 50%. She lives in Arlington, Virginia.

Connect with Sarah on LinkedIn.

Recent Articles

GlaxoSmithKline and Sanofi Stock Rally on EU Vaccine Deal

GlaxoSmithKline and Sanofi stock are rallying in early trading on Friday thanks to news they would supply the EU 300 million vaccine doses.

MRNA Stock: Moderna Rallies Thursday on Vaccine Timeline News

MRNA stock is rallying Thursday on news Moderna will wrap up its late-stage trials by the end of the year. Here's why it matters.

SRNE Stock: Sorrento Therapeutics Pops on Plans to Launch Drug Trials

Sorrento Therapeutics just announced plans to launch human trials of its antibody drug. Here's why else SRNE stock is rallying.

7 Self-Driving Car Companies Racing to Gains

The pandemic may have thrown self-driving car companies a curveball, but it is time to dive into the future with autonomous vehicle stocks.

Eli Lilly Stock Looks Hot on New Antibody Drug Evidence

Eli Lilly stock is climbing slightly higher Wednesday after it became the first company to release antibody drug results.